title: Treatment of amphibians infected with chytrid fungus: learning from failed trials with itraconazole, antimicrobial peptides, bacteria, and heat therapy.
abstract: Amphibian conservation goals depend on effective disease-treatment protocols. Desirable protocols are species, life stage, and context specific, but currently few treatment options exist for amphibians infected with the chytrid fungus Batrachochytrium dendrobatidis (Bd). Treatment options, at present, include antifungal drugs and heat therapy, but risks of toxicity and side-effects make these options untenable in some cases. Here, we report on the comparison of several novel treatments with a more generally accepted antifungal treatment in experimental scientific trials to treat Bd-infected frogs including Alytes obstetricans tadpoles and metamorphs, Bufo bufo and Limnodynastes peronii metamorphs, and Lithobates pipiens and Rana muscosa adults. The experimental treatments included commercial antifungal products (itraconazole, mandipropamid, steriplantN, and PIP Pond Plus), antimicrobial skin peptides from the Bd-resistant Pelophylax esculentus, microbial treatments (Pedobacter cryoconitis), and heat therapy (35°C for 24 h). None of the new experimental treatments were considered successful in terms of improving survival; however, these results may advance future research by indicating the limits and potential of the various protocols. Caution in the use of itraconazole is warranted because of observed toxicity in metamorphic and adult frogs, even at low concentrations. Results suggest that rather than focusing on a single cure-all, diverse lines of research may provide multiple options for treating Bd infection in amphibians. Learning from 'failed treatments' is essential for the timely achievement of conservation goals and one of the primary aims for a publicly accessible treatment database under development.
authors.affiliation: Institute of Evolutionary Biology and Environmental Studies, University of Zurich, Zurich, Switzerland. dwoodhams@gmail.com
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Woodhams
authors.forename: Corina C
authors.initials: CC
authors.lastname: Geiger
authors.forename: Laura K
authors.initials: LK
authors.lastname: Reinert
authors.forename: Louise A
authors.initials: LA
authors.lastname: Rollins-Smith
authors.forename: Brianna
authors.initials: B
authors.lastname: Lam
authors.forename: Reid N
authors.initials: RN
authors.lastname: Harris
authors.forename: Cheryl J
authors.initials: CJ
authors.lastname: Briggs
authors.forename: Vance T
authors.initials: VT
authors.lastname: Vredenburg
authors.forename: Jamie
authors.initials: J
authors.lastname: Voyles
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D023181:Antimicrobial Cationic Peptides / Q000627:therapeutic use*; D001001:Anura; D008411:Chytridiomycota; D005260:Female; D006358:Hot Temperature / Q000627:therapeutic use*; D017964:Itraconazole / Q000627:therapeutic use*; D007814:Larva; D008297:Male; D009181:Mycoses / Q000382:microbiology / Q000628:therapy / Q000662:veterinary*; D019936:Probiotics; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; D017964:Itraconazole